RecruitingPhase 2NCT07071714

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

An Open, Multicenter Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrollment

200 participants

Start Date

Jul 22, 2025

Study Type

INTERVENTIONAL

Conditions

Colorectal, Cancer

Summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-8068 injection in combination with anti-tumor therapies in subjects with colorectal cancer.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new drug called SHR-8068 in combination with other cancer treatments in patients with colorectal cancer. It is a Phase II trial evaluating how well this drug works and what side effects it causes when used alongside standard therapies. **You may be eligible if...** - You are 18 to 75 years old - You have colorectal cancer - You are in good overall health (ECOG 0-1) - You can provide tumor tissue for genetic testing **You may NOT be eligible if...** - You are outside the 18–75 age range - You have serious organ problems - You have active infections or autoimmune conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.